

ADVANTAGENE, INC

Company Information

Company Name
ADVANTAGENE, INC

Address
440 Lexington St
AUBURNDALE, MA, 02466-1923
Phone
n/a

Company Website
n/a
DUNS
192959851

Number of Employees
n/a
Hubzone Owned:
N

Minority Owned:
N
Woman Owned:
N

Award Totals

```
jQuery(document).ready( function() { (function ($) { var program = ['SBIR Phase I', 'SBIR Phase II',  
'STTR Phase I', 'STTR Phase II']; var programCount = [{ "y":6,"amount":"2,145,770.00"}, {"y":2,"amou  
nt":"9,319,195.00"}, {"y":0,"amount":"0.00"}, {"y":0,"amount":"0.00"}]; //var programAmount =  
[2,145,770.00,9,319,195.00,0.00,0.00]; var title = 'Firm Award by Program and Phase'; var  
titleFormat = 'Count: {point.y:0f}'; var titleFormatAmount = 'Amount: ${point.y:.2f}'; var charWidth  
= $('#award-totals-chart-count').width(); charWidth -= 120; $('#award-totals-chart-  
count').highcharts({ chart: { type: 'column' }, title: { text: title }, xAxis: { categories: program,  
labels: { rotation: -45, style: { fontSize: '13px', fontFamily: 'Verdana, sans-serif' } } }, yAxis: { min:  
0, title: { text: 'Awards' } }, legend: { enabled: false }, tooltip: { formatter: function() { return '' +  
this.x + '
```

```
' + 'Award Count: '+ this.y +'  
' + 'Award Amount: $'+ this.point.amount +''; } }, series: [{ name: 'Program/Phase', data:  
programCount, dataLabels: { enabled: false, rotation: -90, color: '#FFFFFF', align: 'right', //format:  
'{point.y:0f}', // no decimal y: 10, // 10 pixels down from the top style: { fontSize: '13px', fontFamily:  
'Verdana, sans-serif' } } } ] }); $("#award_total_table").trigger('click'); })(jQuery); });
```

- [Award Table](#)
- [Award Chart](#)

PROGRAM/PHASE
AWARD AMOUNT (\$)

NUMBER OF AWARDS

SBIR Phase I

\$2,145,770.00

6

SBIR Phase II

\$9,319,195.00

2

Award List

1.

[Combination of GM-CSF with TKR gene therapy](#)

Amount: \$100,000.00

DESCRIPTION (provided by applicant): Combined gene therapy (Herpes Simplex Virus Thymidine Kinase + Anti-herpetic Prodrug) and radiation therapy (TKR therapy) is a novel approach in the armamentarium ...

SBIR Phase I 2003 Department of Health and Human Services

2.

[Clinical study of AdV-tk radiogene therapy for glioma](#)

Amount: \$758,386.00

DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

SBIR Phase I 2004 Department of Health and Human Services

3.

[Clinical study of GMCI in Pancreatic Cancer](#)

Amount: \$747,384.00

DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the US; with less than one-year median survival, it accounts for approximately 30,000 dia ...

SBIR Phase I 2006 Department of Health and Human Services

4.

[Improved system for producing adenoviral vectors](#)

Amount: \$213,871.00

First generation non-replicative adenoviral vectors show promise as anti-cancer agents and as prophylactic vaccines. Current methods for manufacturing these vectors use either the 293 cell line or t ...

SBIR Phase I 2007 Department of Health and Human Services

5.

[Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer](#)

Amount: \$101,130.00

DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

SBIR Phase I 2007 Department of Health and Human Services

6.

[Clinical study of AdV-tk radiogene therapy for malignant glioma](#)

Amount: \$2,092,604.00

DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

SBIR Phase II 2007 Department of Health and Human Services

7.

[Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer](#)

Amount: \$7,226,591.00

DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

SBIR Phase II 2009 Department of Health and Human Services

8.

[Clinically suitable approach for gene-mediated therapy of cirrhosis.](#)

Amount: \$224,999.00

Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhosis ...

SBIR Phase I 2014 Department of Health and Human Services